title: Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection.
abstract: The circadian variation of clinical pharmacokinetics of tacrolimus was studied using 16 adult renal transplant recipients 1 month after the operation. The recipients were administered tacrolimus twice a day (9 a.m. and 9 p.m.), and whole-blood samples were obtained just prior to and 1, 2, 3, 6, 9, and 12 hours after oral administration. Histological specimens of transplant kidney were collected by an allograft core biopsy on day 28 after the transplantation. There were no circadian changes in the area under the concentration-time curve (AUC0-12) (214 ng.h/mL during daytime vs. 223 ng.h/mL during nighttime) resulting from morning and night doses. A slight delay in mean residence time (MRT0-12) and time to the peak concentration (tmax) was found after night doses, but there was no statistical significance. Three patients (18.8%) had a clinical acute rejection (AR) episode 4 to 6 weeks after transplantation, and AUC0-12 at nighttime was significantly lower (18.4% on average) in patients with AR in comparison to those without AR. There was no statistical significance in maximum concentration (Cmax) or morning/night trough levels between patients with and without AR. In regard to the correlation between tacrolimus concentrations in each sampling time and AUC0-12, the morning trough concentrations were less predictable for daytime AUC0-12 (r2 = 0.125), but there was a weak correlation to nighttime AUC0-12 (r2 = 0.424). Tacrolimus concentrations at 2, 3, and 6 hours after the morning dose (C2, C3, and C6) had a good correlation against daytime AUC. The results of this study indicate that the variance on the clinical pharmacokinetics of tacrolimus between daytime and nighttime in renal transplant patients is not significant, while the lower nighttime AUC corresponded to the occurrence of AR.
authors.affiliation: Department of Pharmaceutical Science, Akita University Hospital, Hondo 1-1-1, Akita 010-8543, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tada
authors.forename: Sigeru
authors.initials: S
authors.lastname: Satoh
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iinuma
authors.forename: Naotake
authors.initials: N
authors.lastname: Shimoda
authors.forename: Miho
authors.initials: M
authors.lastname: Murakami
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Hayase
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kato
authors.forename: Toshio
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D002940:Circadian Rhythm; D005260:Female; D006084:Graft Rejection / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus